Cargando…

The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion

BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost s...

Descripción completa

Detalles Bibliográficos
Autores principales: Balfour III, Donald C., Evans, Steven, Januska, Jeff, Lee, Helen Y., Lewis, Sonya J., Nolan, Steve R., Noga, Mark, Stemple, Charles, Thapar, Kishan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2009
Materias:
Cea
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437764/
https://www.ncbi.nlm.nih.gov/pubmed/19125557
http://dx.doi.org/10.18553/jmcp.2009.15.s1.18
_version_ 1785092607750176768
author Balfour III, Donald C.
Evans, Steven
Januska, Jeff
Lee, Helen Y.
Lewis, Sonya J.
Nolan, Steve R.
Noga, Mark
Stemple, Charles
Thapar, Kishan
author_facet Balfour III, Donald C.
Evans, Steven
Januska, Jeff
Lee, Helen Y.
Lewis, Sonya J.
Nolan, Steve R.
Noga, Mark
Stemple, Charles
Thapar, Kishan
author_sort Balfour III, Donald C.
collection PubMed
description BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost shifting have the potential to hamper the future of the Part D benefit. OBJECTIVES: To discuss factors that will likely have the most impact on the future of Medicare Part D from a patient and payer perspective. SUMMARY: The continued growth of the elderly population is expected to place an increasing burden on the services provided through Medicare. Given the current financial situation, it has been predicted that Medicare's Hospital Insurance Trust Fund will be depleted by 2019. To provide quality benefits and remain competitive, health plans are continually evaluating and redesigning their Part D benefits. However, the current regulatory environment is preventing plans from offering nnovative products and designs that could lower costs to beneficiaries. The growing number of beneficiaries hitting the doughnut hole is also becoming a concern for both beneficiaries and health plans. More beneficiaries are reaching the doughnut hole, and this has resulted in changes in beneficiary behaviors, including stopping medications, switching to alternative drug classes, and reducing medication use. Because of the increasing concerns about Medicare's sustainability, it is anticipated that the government may become more involved. CONCLUSIONS: As the health care landscape continues to change, payers will be challenged to offer benefit designs that are affordable to elderly beneficiaries. For its part, the government must allow plans to design benefits that will improve the overall quality of care. Additionally, closer attention must be given to the growing number of beneficiaries hitting the doughnut hole and its potential adverse clinical and economic consequences.
format Online
Article
Text
id pubmed-10437764
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104377642023-08-21 The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion Balfour III, Donald C. Evans, Steven Januska, Jeff Lee, Helen Y. Lewis, Sonya J. Nolan, Steve R. Noga, Mark Stemple, Charles Thapar, Kishan J Manag Care Pharm Cea BACKGROUND: The Medicare Prescription Drug, Improvement, and Modernization Act, signed into law in 2003, provided access to prescription drugs for elderly Americans. The Part D benefit continues to evolve. Changes in plan designs, he impact of the doughnut hole on beneficiaries, and increased cost shifting have the potential to hamper the future of the Part D benefit. OBJECTIVES: To discuss factors that will likely have the most impact on the future of Medicare Part D from a patient and payer perspective. SUMMARY: The continued growth of the elderly population is expected to place an increasing burden on the services provided through Medicare. Given the current financial situation, it has been predicted that Medicare's Hospital Insurance Trust Fund will be depleted by 2019. To provide quality benefits and remain competitive, health plans are continually evaluating and redesigning their Part D benefits. However, the current regulatory environment is preventing plans from offering nnovative products and designs that could lower costs to beneficiaries. The growing number of beneficiaries hitting the doughnut hole is also becoming a concern for both beneficiaries and health plans. More beneficiaries are reaching the doughnut hole, and this has resulted in changes in beneficiary behaviors, including stopping medications, switching to alternative drug classes, and reducing medication use. Because of the increasing concerns about Medicare's sustainability, it is anticipated that the government may become more involved. CONCLUSIONS: As the health care landscape continues to change, payers will be challenged to offer benefit designs that are affordable to elderly beneficiaries. For its part, the government must allow plans to design benefits that will improve the overall quality of care. Additionally, closer attention must be given to the growing number of beneficiaries hitting the doughnut hole and its potential adverse clinical and economic consequences. Academy of Managed Care Pharmacy 2009-01 /pmc/articles/PMC10437764/ /pubmed/19125557 http://dx.doi.org/10.18553/jmcp.2009.15.s1.18 Text en Copyright © 2009, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Cea
Balfour III, Donald C.
Evans, Steven
Januska, Jeff
Lee, Helen Y.
Lewis, Sonya J.
Nolan, Steve R.
Noga, Mark
Stemple, Charles
Thapar, Kishan
The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title_full The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title_fullStr The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title_full_unstemmed The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title_short The Future of Medicare Part D Drug Plans—Results From a Roundtable Discussion
title_sort future of medicare part d drug plans—results from a roundtable discussion
topic Cea
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437764/
https://www.ncbi.nlm.nih.gov/pubmed/19125557
http://dx.doi.org/10.18553/jmcp.2009.15.s1.18
work_keys_str_mv AT balfouriiidonaldc thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT evanssteven thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT januskajeff thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT leeheleny thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT lewissonyaj thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT nolanstever thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT nogamark thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT stemplecharles thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT thaparkishan thefutureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT balfouriiidonaldc futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT evanssteven futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT januskajeff futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT leeheleny futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT lewissonyaj futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT nolanstever futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT nogamark futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT stemplecharles futureofmedicarepartddrugplansresultsfromaroundtablediscussion
AT thaparkishan futureofmedicarepartddrugplansresultsfromaroundtablediscussion